Explore data about our technology appraisal guidance. Find out about the decisions we make and our ways of working.
NICE has recommended the scan as a first-line investigation for people with suspected clinically localised prostate cancer.
NICE has published final draft guidance recommending a breakthrough cancer treatment, called CAR T-cell therapy, for adults with certain types of non-Hodgkin lymphoma.
Healthcare professionals should consider the risk of antimicrobial resistance when deciding whether antibiotics are needed for treating or preventing a flare up of symptoms of chronic obstructive pulmonary disease (COPD).
Up to 400 patients each year are set to benefit from the procedure being made available more widely
Jane Gorringe, maternity engagement project manager at Tamba discusses how babies’ lives can be saved if maternity units adhere to NICE guidance on multiple pregnancies.
Approving regorafenib is a "welcome step forward" for those people who are eligible
Meindert Boysen explains how NICE is helping to get transformative healthcare technologies to patients quicker
Patients with acute ischaemic stroke should be offered a procedure to remove the blood clot up to 24 hours after the onset of symptoms.
Hayley Clark, senior business development manager, NSPCC, outlines how NICE and the NSPCC support mental health services tailored to children’s needs
Thousands of lung cancer patients are now eligible for a new life-extending treatment through the Cancer Drugs Fund (CDF).
Sarah Fishburn, quality improvement for Thames Valley Strategic Clinical Network, discusses how postnatal mental health care can be improved
Patients with a type of advanced skin cancer have a new treatment option as pembrolizumab, also known as Keytruda, has been recommended for use on the Cancer Drugs Fund.
NICE has recommended a pioneering cancer treatment, CART-cell therapy, for people under the age of 25 with leukaemia.
Matthew Parris, Healthwatch deputy CEO, shares his experience of visiting care homes with Healthwatch Surrey
Following improved access and optimisation of the website, the NICE guidance app will no longer be available for download with plans to phase it out by January 2019.
Funding available to academics and researchers to develop new methods and techniques for diagnostic technologies
NICE has announced the appointment of Jeanette Kusel as director for NICE Scientific Advice.
The contractor establishes and maintains a register of patients with atrial fibrillation, including patients with 'AF resolved' Subject(s):
The percentage of patients with diabetes with moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the...
The percentage of patients with a diagnosis of type 2 diabetes and a recorded CVD risk assessment score of ≥10% (without moderate or severe frailty),...
The percentage of patients aged 25–84 years, with a diagnosis of type 2 diabetes, without moderate or severe frailty, not currently treated with a...
The percentage of patients with diabetes aged 40 years and over, with no history of CVD and without moderate or severe frailty, who are currently...
The percentage of patients with diabetes and a history of CVD (excluding haemorrhagic stroke) who are currently treated with a statin
Natasha Sloman, head of Hospital Inspection at the Care Quality Commission (CQC), discusses how working with NICE has been fundamental in making her work a success
The percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in...
Of the patients with type 1 diabetes who meet the following criteria: aged over 40 years and who have either had diabetes for more than 10 years, or...
Paige Ataou shares her experience of mental health in the changing world and talks about environment and relationships
Women should be offered the treatment option of their choice, in discussion with their clinician
Katie Currie, public health principal, outlines how the NICE Scholar programme shaped her career development
Nageena Khalique QC, barrister and chair of the committee for the NICE guideline on Decision making and mental capacity, discusses how the new guideline applies to a range of situations
Dialysis choice allows patients to live the life they want to
The 2019 Shared Learning Awards are now open for entries.
People who incorrectly believe they are allergic to penicillin are unnecessarily put at an increased risk of developing MRSA or C difficile, NICE warns today.
A new NICE quality standard (QS) on eating disorders focuses on promoting early access and coordinating care between services.
Driver training and car sharing should also be considered in bid to reduce emissions
CAR-T is too expensive to recommend as a treatment for adults with lymphoma, NICE says in draft guidance today (19 September).
Dr Julia Terry discussed how her experience as a NICE Fellow enhanced her academic career
Hundreds of patients with a type of advanced skin cancer are set to benefit from a new treatment, dabrafenib plus trametinib.
Dr Finnikin explains how he approaches patients about cardiovascular risk and changes to lifestyle
Procedure could be an option for adults with severe asthma whose symptoms cannot be adequately controlled with drugs
CAR-T considered to be an exciting innovation which can cure some patients but very expensive
People should take honey or cough medicines instead but speak to their GP if it persists for longer than three weeks
NICE hopes for further talks over nusinersen for treating a rare genetic disorder; spinal muscular atrophy (SMA).
Naomi introduces the NICE into Action webinar series and tells us why this is important for the allied health professions.
NICE has published a draft guideline on the care and support adults with cerebral palsy should receive.
Eleanor describes how a new system to comment on draft guidance will better support NICE stakeholders and staff during consultations
A new master’s degree in healthcare decision making has been launched by London School of Economics and Political Science (LSE) in collaboration with NICE.
Around 60% of children with high-risk neuroblastoma could be treated with dinutuximab beta
Hundreds of patients a year set to benefit from roll out of dye to all of England’s neurosurgical units